Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion - PubMed (original) (raw)

. 1999 Aug 13;274(33):23223-8.

doi: 10.1074/jbc.274.33.23223.

Affiliations

• PMID: 10438495
• DOI: 10.1074/jbc.274.33.23223

Free article

Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion

R A Cherny et al. J Biol Chem. 1999.

Free article

Abstract

Zn(II) and Cu(II) precipitate Abeta in vitro into insoluble aggregates that are dissolved by metal chelators. We now report evidence that these biometals also mediate the deposition of Abeta amyloid in Alzheimer's disease, since the solubilization of Abeta from post-mortem brain tissue was significantly increased by the presence of chelators, EGTA, N,N,N',N'-tetrakis(2-pyridyl-methyl) ethylene diamine, and bathocuproine. Efficient extraction of Abeta also required Mg(II) and Ca(II). The chelators were more effective in extracting Abeta from Alzheimer's disease brain tissue than age-matched controls, suggesting that metal ions differentiate the chemical architecture of amyloid in Alzheimer's disease. Agents that specifically chelate copper and zinc ions but preserve Mg(II) and Ca(II) may be of therapeutic value in Alzheimer's disease.

PubMed Disclaimer

Similar articles

• Interactions of Zn(II) and Cu(II) ions with Alzheimer's amyloid-beta peptide. Metal ion binding, contribution to fibrillization and toxicity.
  Tõugu V, Tiiman A, Palumaa P. Tõugu V, et al. Metallomics. 2011 Mar;3(3):250-61. doi: 10.1039/c0mt00073f. Epub 2011 Feb 25. Metallomics. 2011. PMID: 21359283 Review.
• Metal ions and intrinsically disordered proteins and peptides: from Cu/Zn amyloid-β to general principles.
  Faller P, Hureau C, La Penna G. Faller P, et al. Acc Chem Res. 2014 Aug 19;47(8):2252-9. doi: 10.1021/ar400293h. Epub 2014 May 29. Acc Chem Res. 2014. PMID: 24871565
• Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.
  Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI. Cherny RA, et al. Neuron. 2001 Jun;30(3):665-76. doi: 10.1016/s0896-6273(01)00317-8. Neuron. 2001. PMID: 11430801
• Metal Ions in Alzheimer's Disease: A Key Role or Not?
  Liu Y, Nguyen M, Robert A, Meunier B. Liu Y, et al. Acc Chem Res. 2019 Jul 16;52(7):2026-2035. doi: 10.1021/acs.accounts.9b00248. Epub 2019 Jul 5. Acc Chem Res. 2019. PMID: 31274278
• Cu and Zn interactions with Aβ peptides: consequence of coordination on aggregation and formation of neurotoxic soluble Aβ oligomers.
  Rana M, Sharma AK. Rana M, et al. Metallomics. 2019 Jan 23;11(1):64-84. doi: 10.1039/c8mt00203g. Metallomics. 2019. PMID: 30234208 Review.

Cited by

• Persistent infections, immune-senescence and Alzheimer's disease.
  Licastro F, Porcellini E. Licastro F, et al. Oncoscience. 2016 Jun 30;3(5-6):135-42. doi: 10.18632/oncoscience.309. eCollection 2016. Oncoscience. 2016. PMID: 27489858 Free PMC article.
• Dietary magnesium and copper affect survival time and neuroinflammation in chronic wasting disease.
  Nichols TA, Spraker TR, Gidlewski T, Cummings B, Hill D, Kong Q, Balachandran A, VerCauteren KC, Zabel MD. Nichols TA, et al. Prion. 2016 May 3;10(3):228-50. doi: 10.1080/19336896.2016.1181249. Prion. 2016. PMID: 27216881 Free PMC article.
• Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice.
  Lee JY, Cole TB, Palmiter RD, Suh SW, Koh JY. Lee JY, et al. Proc Natl Acad Sci U S A. 2002 May 28;99(11):7705-10. doi: 10.1073/pnas.092034699. Proc Natl Acad Sci U S A. 2002. PMID: 12032347 Free PMC article.
• The processing of eIF4GI by human rhinovirus type 2 2A(pro): relationship to self-cleavage and role of zinc.
  Glaser W, Triendl A, Skern T. Glaser W, et al. J Virol. 2003 Apr;77(8):5021-5. doi: 10.1128/jvi.77.8.5021-5025.2003. J Virol. 2003. PMID: 12663811 Free PMC article.
• Vaccines for Alzheimer's disease: how close are we?
  Janus C. Janus C. CNS Drugs. 2003;17(7):457-74. doi: 10.2165/00023210-200317070-00001. CNS Drugs. 2003. PMID: 12751917 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information